Poll: Strong opposition to Trump policy of separating immigrant children from parents

WASHINGTON – Americans voters oppose the Trump administration’s policy of separating immigrant children from their parents by a large margin — 66 to 27 percent —  a new Quinnipiac University poll shows. The same poll, released Monday, indicated American voters also support, 79 – 15 percent, allowing immigrants who were brought to the United States  as children, known as “dreamers,” to remain here and ultimately to apply for citizenship.    Continue Reading →

A crash course on luring sports betting from the shadows

It was an eclectic audience at a seminar to learn about a business still illegal in Connecticut, if for the moment. There was an OTB guy from Suffolk, N.Y., a casino and horse-track general manager from Ruidoso Downs, N.M., the Harvard-educated consumer-protection commissioner of Connecticut, and three silent observers from the National Hockey League.
The agenda: How to make a buck by taking bets on sports. Continue Reading →

House set to vote on GOP immigration bills that CT Dems are likely to oppose

WASHINGTON– The U.S. House plans to vote on two immigration bills this week aimed at helping young immigrants known as “dreamers” and ending the practice of separating children at the border from their undocumented parents.. But there’s no guarantee either bill will pass, and neither is expected to win the support of Connecticut’s Democratic U.S. House members. Continue Reading →

How America got hooked on a deadly drug

Purdue Pharma left almost nothing to chance in its whirlwind marketing of its new painkiller OxyContin. From 1996 to 2002, Purdue pursued nearly every avenue in the drug supply and prescription sales chain — a strategy now cast as reckless and illegal in more than 1,500 federal civil lawsuits from communities in Florida to Wisconsin to California that allege the drug has fueled a national epidemic of addiction. Kaiser Health News is releasing years of Purdue’s internal budget documents and other records to offer readers a chance to evaluate how the privately held Connecticut company spent hundreds of millions of dollars to launch and promote the drug, a trove of information made publicly available here for the first time. All of these internal Purdue records were obtained from a Florida attorney general’s office investigation of Purdue’s sales efforts that ended late in 2002. I have had copies of those records in my basement for years. Continue Reading →